There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ANI Pharmaceuticals Inc (ANIP) and ChemoCentryx (CCXI) with bullish sentiments.
ANI Pharmaceuticals Inc (ANIP)
In a report released today, Dewey Steadman from Canaccord Genuity maintained a Buy rating on ANI Pharmaceuticals Inc, with a price target of $70. The company’s shares closed on Friday at $52.66, close to its 52-week low of $48.40.
According to TipRanks.com, Steadman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.9% and a 32.8% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, Pacira Pharmaceuticals, and Correvio Pharma Corp.
ANI Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $72, representing a 36.7% upside. In a report issued on November 6, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $74 price target.
.
See today’s analyst top recommended stocks >>
ChemoCentryx (CCXI)
In a report released today, Michelle Gilson from Canaccord Genuity maintained a Buy rating on ChemoCentryx, with a price target of $20. The company’s shares closed on Friday at $10.05.
According to TipRanks.com, Gilson is a 4-star analyst with an average return of 26.9% and a 51.6% success rate. Gilson covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Retrophin, and BioMarin.
ChemoCentryx has an analyst consensus of Moderate Buy, with a price target consensus of $15.83, representing a 57.5% upside. In a report issued on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $20 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
